Literature DB >> 9668364

Molecular mimicry in Guillain-Barré syndrome.

K A Sheikh1, T W Ho, I Nachamkin, C Y Li, D R Cornblath, A K Asbury, J W Griffin, G M McKhann.   

Abstract

Guillain-Barré syndrome (GBS) is the commonest cause of acute flaccid paralysis worldwide. Recent pathological and electrodiagnostic studies indicated that there are different patterns within this syndrome. The demyelinating pattern predominates in North America and Europe, whereas axonal variants of GBS occur more frequently in Northern China. Infection with Campylobacter jejuni is one of the most frequently recognized antecedent events in all variants of GBS. The lipopolysaccharides of these organisms share ganglioside-like epitopes with peripheral nerves, and patients with GBS have antiganglioside antibodies. These observations have given rise to the hypothesis that "molecular mimicry" is the immunopathogenic mechanism of injury to peripheral nerve fibers. With this hypothesis in view, we summarize our experience of GBS as it occurs in Northern China. To explore the role of molecular mimicry in this cohort we sought evidence of preceding Campylobacter infection and correlated this with clinical characteristics and antiganglioside serology. Based on our results we propose a sequence of pathogenic events leading to peripheral nerve injury in GBS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668364     DOI: 10.1111/j.1749-6632.1998.tb09683.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

2.  Capsular genotype and lipooligosaccharide locus class distribution in Campylobacter jejuni from young children with diarrhea and asymptomatic carriers in Bangladesh.

Authors:  Z Islam; S K Sarker; I Jahan; K S Farzana; D Ahmed; A S G Faruque; P Guerry; F Poly; A P Heikema; H P Endtz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-21       Impact factor: 3.267

3.  Neurologic symptoms associated with cattle farming in the agricultural health study.

Authors:  Leora Vegosen; Meghan F Davis; Ellen Silbergeld; Patrick N Breysse; Jacqueline Agnew; Gregory Gray; Laura Beane Freeman; Freya Kamel
Journal:  J Occup Environ Med       Date:  2012-10       Impact factor: 2.162

4.  Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.

Authors:  J Schessl; M Koga; K Funakoshi; J Kirschner; W Muellges; A Weishaupt; R Gold; R Korinthenberg
Journal:  Arch Dis Child       Date:  2006-08-18       Impact factor: 3.791

5.  Anti-glycolipid GM2-positive Guillain-Barre syndrome due to hepatitis E infection.

Authors:  S Cronin; R McNicholas; E Kavanagh; V Reid; K O'Rourke
Journal:  Ir J Med Sci       Date:  2010-11-10       Impact factor: 1.568

Review 6.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

7.  Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.

Authors:  Tyrone Bowes; Eric R Wagner; Judith Boffey; Dawn Nicholl; Lynne Cochrane; Mustapha Benboubetra; Joe Conner; Keiko Furukawa; Koichi Furukawa; Hugh J Willison
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

8.  Fcγ receptor-mediated inflammation inhibits axon regeneration.

Authors:  Gang Zhang; Nataliia Bogdanova; Tong Gao; Julia J Song; Mark S Cragg; Martin J Glennie; Kazim A Sheikh
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

Review 9.  Revisiting Campylobacter jejuni Virulence and Fitness Factors: Role in Sensing, Adapting, and Competing.

Authors:  Abdi Elmi; Fauzy Nasher; Nick Dorrell; Brendan Wren; Ozan Gundogdu
Journal:  Front Cell Infect Microbiol       Date:  2021-02-03       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.